New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 17, 2013
08:04 EDTALNYAlnylam announces proof-of-concept data from RNAi program
Alnylam announced that it has presented pre-clinical proof-of-concept data from its RNAi therapeutic program targeting aminolevulinate synthase-1 for the treatment of porphyria including acute intermittent porphyria. "The new research results support the advancement of RNAi therapeutics as a promising strategy for the prevention and/or treatment of acute attacks in patients with AIP," the company said. It added, "In particular, a prototype GalNAc-siRNA targeting ALAS-1 was shown to be effective in blocking ALA and PBG production in both prophylactic and treatment models of AIP. The company is on track to designate a GalNAc-siRNA development candidate, ALN-AS1, in late 2013 resulting in an investigational new drug (IND) filing in 2014."
News For ALNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 2, 2016
08:36 EDTALNYPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
February 1, 2016
08:03 EDTALNYAlnylam completes enrollment in APOLLO Phase 3 study with Patisiran
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use